Artis Truett, MD
Dermatology · Owensboro, KYNPI 1215042429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for dermatology clinicians in KY, where the typical reported total is $4,057.
Across 119 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$392
- AbbVie$391
- Organogenesis Inc.$238
- Novartis$184
- Regeneron Healthcare Solutions, Inc.$144
- E.r. Squibb & Sons, L.L.C.$140
- plus $560 from 13 others
Across 226 payments — averaging $6211.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$526K
- Pfizer$243K
- Janssen Research & Development, LLC$242K
- UCB SA$195K
- UCB Biosciences Inc.$50K
- Sun Pharmaceutical Industries Inc.$42K
- plus $106K from 5 others
What the payments were for
- Food & beverage$1,86691%
- Education$1839%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $392 |
| AbbVie(2 entities) | 28 | $391 |
| Organogenesis Inc. | 7 | $238 |
| Novartis | 10 | $184 |
| Regeneron Healthcare Solutions, Inc. | 10 | $144 |
| E.r. Squibb & Sons, L.L.C. | 10 | $140 |
| Sun Pharmaceutical Industries Inc. | 5 | $114 |
| Amgen | 6 | $91 |
| Sanofi | 4 | $60 |
| LEO Pharma Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $48 |
| Biofrontera Inc. | 3 | $44 |
| Arcutis Biotherapeutics, Inc. | 3 | $42 |
| UCB, Inc. | 2 | $37 |
| Boehringer Ingelheim | 1 | $20 |
| Mimedx Group, Inc. | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Reprise Biomedical, Inc. | 1 | $14 |
| Pfizer | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOVACHOR$106
How this compares
$2,049 in reported general payments places this provider in the 30th percentile of 128 dermatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 11 | $162,420 |
| OtezlaApremilast | 22 | $106,939 |
| Humira PenAdalimumab | 15 | $106,539 |
| Taltz AutoinjectorIxekizumab | 13 | $88,462 |
| Fluorouracil | 60 | $3,959 |
| Clobetasol Propionate | 77 | $3,118 |
| Ketoconazole | 83 | $1,504 |
| Dapsone | 20 | $1,218 |
| Fluticasone Propionate | 60 | $1,163 |
| Doxycycline Hyclate | 56 | $1,087 |
| Minocycline Hcl | 43 | $1,013 |
| Triamcinolone Acetonide | 91 | $948 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 30 | $646 |
| ValacyclovirValacyclovir Hcl | 29 | $634 |
| Mupirocin | 64 | $476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $91 | $106,93922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 128 dermatology providers in Kentucky.
Other dermatology in Owensboro
- Sandra CoxOwensboro$6K
- Leon KircikLousiville$4.5M
- Melissa KnucklesCorbin$1.5M
- James WhartonLexington$1.2M
- James JacksonLouisville$326K
- James AllredFranklin$294K
- Jae JungLouisville$188K
- Tanner ParrentHopkinsville$174K
- Clint TuckerLouisville$50K
- Andrea WaldmanLexington$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.